ARTIMPLANT INTERIM REPORT JANUARY - JUNE 2011

| Source: Artimplant AB Artimplant AB 

ARTIMPLANT INTERIM REPORT JANUARY - JUNE 2011

First six months

  · Net revenue amounted to SEK 9.7 million (9.8).*
  · The net loss totaled SEK 9.0 million (9.8).  
  · Earnings per stock unit amounted to SEK -0.08 (-0.16).
  · The result was affected by one-off items amounting to -0.9 million
(-).
  · Artimplant's own sales as a proportion of total sales continued to
increase and accounted for 72% (57) of product sales.
  · The Company has revised its cash flow target and the aim now is that
a positive cash flow before changes in working capital will be achieved
on a monthly basis during the first quarter of 2012 (previously the
target was by the end of 2011).

Second quarter

  · Net revenue amounted to SEK 4.3 million (5.1).*
  · The net loss totaled SEK 5.2 million (5.0).  
  · Earnings per stock unit amounted to SEK -0.04 (-0.08).
  · The result was affected by one-off items amounting to -0.9 million
(-).

Events after the period-end

  ·
Decision has been taken by the Company to open its own sales office in
theUSA.

N. B. This is a translation from Swedish. The Swedish version shall
always take precedence.

Artimplant will not hold a telephone conference by reason of this
report. For further information see www.artimplant.com.

* Figures in brackets refer to the corresponding period last year

For additional information, please contact:
Kjell Thörnbring, CEO, phone +46 (0)31-746 56 54, +46 (0)703 11 90 25,
kjell.thornbring @artimplant.com (lars-johan.cederbrant@artimplant.com)

Further information at www.artimplant.com (http://www.artimplant.com/)
where one also can subscribe to future press releases;
www.artimplant.com/investors-media/subscribe-to-press-releases.html (htt
p://www.artimplant.com/investors-media/subscribe-to-press-releases.html)

Artimplant
Artimplant's mission is to restore the health of patients by offering
medical professionals degradable implants that help the body to heal.

Artimplant is a medical technology company that restores health through
the development, production and marketing of degradable implants that
regenerate body functions and improve quality of life. Our products are
made from Artelon®, a biomaterial developed by the Company. Artimplant
produces implants for the treatment of osteoarthritis in hands and feet,
shoulder and other soft tissue injuries as well as oral and veterinary
applications. The Company's products are sold through licensees and own
sales under Artimplant's brand take place through agents and
distributors.

Artimplant is a public company listed on the NASDAQ OMX Stockholm in the
Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in
theU.S.Private Securities Litigation Reform Act of 1995. Readers are
cautioned not to place undue reliance on these forward-looking
statements. Actual results may differ materially from those indicated by
these forward-looking statements as a result of risks and uncertainties
impacting the Company's business including increased competition; the
ability of the Company to expand its operations and to attract and
retain qualified professionals; technological obsolescence; general
economic conditions; and other risks detailed from time to time in the
Company's filings.

This is information which Artimplant shall make public pursuant to the
Swedish Financial Instruments Act and the Swedish Securities Exchange
and Clearing Operations Act and/or stock market agreements. Information
was made available for publication on August 3, 2011 at 9:00 AM (CET).

Attachments